bioRxivCell Biology
Cisplatin-inducible death receptor 5 antisense long non-coding RNA modulates cell cycle and proliferation in HeLa cells
Abstract
Cisplatin is a chemotherapeutic drug with pleiotropic effects known to modulate the expression of long non-coding RNAs (lncRNAs). With the annotation of many novel lncRNAs, it is imperative to employ a more comprehensive approach to identify cisplatin-mediated changes in the expression of lncRNAs. Next generation sequencing (NGS)-based profiling of total RNAs from cisplatin-treated HeLa cells identified 3489 expressed lncRNAs, of which 1930 and 1051 were up- and downregulated upon cisplatin treatment, respectively. For functional analyses, we selected one of the cisplatin inducible lncRNAs situated antisense to the death receptor 5 and thus named death receptor 5 antisense lncRNA (DR5-AS). Knock-down of DR5-AS lncRNA caused a morphological change in cell shape without inducing any cell death. A second round of NGS-based profiling of total RNAs from DR5-AS-silenced cells revealed differential expression of genes associated with the immune system and cell cycle. Further analyses showed that DR5-AS reduces cell proliferation and causes a cell cycle arrest at S and G2/M phases. These results suggest that cisplatin-mediated reduction in cell proliferation and cell cycle may be mediated by long non-coding RNAs. SignificanceCisplatin is known to induce DNA-damage-induced cell death, which is used in combination chemotherapies in various cancer types. However, many patients develop resistance to cisplatin, which involves both protein-coding and noncoding genes. Although a number of long noncoding RNAs are linked to cisplatin resistance, a more comprehensive study is required. In this study, we took advantage of next-generation-sequencing based lncRNA profiling to unveil the extent of cisplatin inducible lncRNAs in HeLa cells. Additionally, we functionally characterized one of the cisplatin-inducible lncRNA, death receptor 5 antisense. Interestingly, this spesific lncRNA modulates cell morphology, proliferation and cell cycle without affecting cell death.
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- LncRNA MIR4435-2HG mediates cisplatin resistance in HCT116 cells by regulating Nrf2 and HO-1
X. Zhong, P. Luo, … ShuGui Wu,ChaoMing Zhou,Xia Yuan,HongMi Li,JinPing Chen,YunFei Tian,Yang Qiu,XiaoMing Zhong, Ping Luo·bioRxiv·Sep 13, 2019
- Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities
Roberta Esposito, Taisia Polidori, … Rory Johnson·Cell GenomicsPeer-reviewed·Aug 22, 2022
- A Non-Genetic, Cell Cycle Dependent Mechanism of Platinum Resistance in Lung Adenocarcinoma
A. Gonzalez-Rajal, K. Marzec, … A. Burgess·bioRxiv·Nov 26, 2020
- Identification of a long non-coding RNA regulator of liver carcinoma cell survival
Y. Rybakova, J. Gonzalez, … D. Anderson·bioRxiv·Jul 1, 2020
- Inducing oncolytic cell death in human cancer cells by the long non-coding RNA let-A
T. Birbaumer, T. B. Schlumpf, … R. Paro·bioRxiv·Jul 16, 2021
- RNA splicing variants of the novel long non-coding RNA, CyKILR, possess divergent biological functions in non-small cell lung cancer
Xiujie Xie, H. Patrick MacKnight, … Charles Edward Chalfant·Molecular Therapy — Nucleic AcidsPeer-reviewed·Dec 5, 2024